A prospective, observational, study comparing T cell responses to mRNA-based COVID-19 vaccines between patients with rheumatic diseases and multiple sclerosis treated with anti-CD20 therapy and immunocompetent controls
Latest Information Update: 29 Nov 2021
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 29 Nov 2021 New trial record
- 17 Nov 2021 Results published in the Clinical Infectious Diseases